Live probiotic instability leads to inconsistent therapeutic dosing and short shelf life. Engineering specific non-viable metabolic byproducts ensures bioactive consistency and product stability.
Neonatal microbiomes often lack the metabolic versatility to process both maternal and solid food carbohydrate sources simultaneously. Establishing early microbial dominance prevents pathogenic infiltration and supports developmental nutrition.